AR044029A2 - Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura - Google Patents

Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura

Info

Publication number
AR044029A2
AR044029A2 ARP040101329A AR044029A2 AR 044029 A2 AR044029 A2 AR 044029A2 AR P040101329 A ARP040101329 A AR P040101329A AR 044029 A2 AR044029 A2 AR 044029A2
Authority
AR
Argentina
Prior art keywords
processes
ritonavir
preparation
substantially pure
polymorm
Prior art date
Application number
Other languages
English (en)
Inventor
A Saleki-Gerhardt
J Bauer
B Narayanan
S Chemburkar
K Patel
P Bauer
K Allen
H Spiwek
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044029(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR044029A2 publication Critical patent/AR044029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Ritonavir amorfo sustancialmente puro, caracterizado por una transición vítrea desde alrededor de 45ºC a alrededor de 49ºC. También se describen procesos para su preparación y los procesos para preparar la Forma polimorfa cristalina I de ritonavir sustancialmente pura. Estos compuestos son útiles como inhibidores de la proteasa del virus de la inmunodeficiencia humana (HIV).
ARP040101329 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura AR044029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
AR044029A2 true AR044029A2 (es) 2005-08-24

Family

ID=26817251

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Country Status (29)

Country Link
EP (4) EP2298751A3 (es)
JP (4) JP4815050B2 (es)
KR (3) KR100793046B1 (es)
CN (5) CN1310715B (es)
AR (5) AR019431A1 (es)
AT (3) ATE425974T1 (es)
AU (1) AU768207B2 (es)
BG (4) BG65150B1 (es)
BR (1) BR9912010A (es)
CA (3) CA2337846C (es)
CO (1) CO5090830A1 (es)
CY (2) CY1111600T1 (es)
CZ (2) CZ307116B6 (es)
DE (2) DE69940616D1 (es)
DK (3) DK1418174T3 (es)
ES (3) ES2372990T3 (es)
HU (3) HU229999B1 (es)
ID (1) ID27996A (es)
IL (4) IL140492A0 (es)
MY (2) MY121765A (es)
NO (2) NO318385B1 (es)
NZ (2) NZ522690A (es)
PL (2) PL213978B1 (es)
PT (3) PT1418174E (es)
SI (3) SI1418174T1 (es)
SK (3) SK287586B6 (es)
TR (1) TR200100171T2 (es)
TW (3) TWI227713B (es)
WO (1) WO2000004016A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
MXPA03010771A (es) * 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
WO2008041176A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
CA2170020C (en) * 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.

Also Published As

Publication number Publication date
SK287381B6 (sk) 2010-08-09
CZ307116B6 (cs) 2018-01-24
CY1112139T1 (el) 2015-11-04
DK1418174T3 (da) 2009-05-18
MY145265A (en) 2012-01-13
EP2017269A3 (en) 2009-06-10
KR100853371B1 (ko) 2008-08-22
CZ298188B6 (cs) 2007-07-18
AR019431A1 (es) 2002-02-20
CZ2001203A3 (en) 2001-05-16
AU768207B2 (en) 2003-12-04
MY121765A (en) 2006-02-28
DE69940616D1 (de) 2009-04-30
BG105197A (en) 2001-10-31
BG65963B1 (bg) 2010-07-30
IL140492A (en) 2010-12-30
IL140492A0 (en) 2002-02-10
HU229999B1 (en) 2015-04-28
TW200716550A (en) 2007-05-01
SK286388B6 (sk) 2008-09-05
EP2017269A9 (en) 2009-10-14
EP1097148B1 (en) 2004-03-17
AR059763A2 (es) 2008-04-30
KR100793046B1 (ko) 2008-01-10
TWI271400B (en) 2007-01-21
ID27996A (id) 2001-05-03
CA2337846C (en) 2006-02-21
NO20042393L (no) 2001-01-18
HUP0103823A3 (en) 2003-05-28
AU5003799A (en) 2000-02-07
KR20010072003A (ko) 2001-07-31
TWI227713B (en) 2005-02-11
CN1310715A (zh) 2001-08-29
IL191582A (en) 2016-02-29
KR20060118022A (ko) 2006-11-17
DK1097148T3 (da) 2004-04-26
EP1097148A2 (en) 2001-05-09
HU0800266D0 (en) 2008-06-30
EP2017269A8 (en) 2009-09-30
AR049658A2 (es) 2006-08-23
CA2510949C (en) 2009-11-17
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
JP2017061475A (ja) 2017-03-30
EP2298751A3 (en) 2011-08-17
BG109682A (bg) 2007-03-30
EP2017269A2 (en) 2009-01-21
HK1121155A1 (en) 2009-04-17
SK922001A3 (en) 2001-07-10
WO2000004016A2 (en) 2000-01-27
CZ2006533A3 (cs) 2001-05-16
DE69915628D1 (en) 2004-04-22
PL213978B1 (pl) 2013-05-31
TWI362382B (en) 2012-04-21
EP1418174A2 (en) 2004-05-12
CA2674800A1 (en) 2000-01-27
AR059764A2 (es) 2008-04-30
KR100740796B1 (ko) 2007-07-20
ATE534636T1 (de) 2011-12-15
NO20010298L (no) 2001-01-18
CN1310715B (zh) 2010-11-03
KR20040081137A (ko) 2004-09-20
CN101966180A (zh) 2011-02-09
EP2298751A2 (en) 2011-03-23
JP5732212B2 (ja) 2015-06-10
NZ509125A (en) 2003-02-28
JP2010270135A (ja) 2010-12-02
IL191582A0 (en) 2008-12-29
CN1502613A (zh) 2004-06-09
NO318385B1 (no) 2005-03-14
SI2017269T1 (sl) 2012-02-29
HU230150B1 (hu) 2015-09-28
WO2000004016A3 (en) 2000-03-30
IL187181A (en) 2009-09-01
EP1418174B1 (en) 2009-03-18
HUP0103823A2 (hu) 2002-02-28
JP4815050B2 (ja) 2011-11-16
HU227540B1 (en) 2011-08-29
HU0800267D0 (en) 2008-06-30
CN101259128A (zh) 2008-09-10
DE69915628T2 (de) 2004-08-12
NZ522690A (en) 2004-04-30
BG65150B1 (bg) 2007-04-30
ATE261947T1 (de) 2004-04-15
NO20010298D0 (no) 2001-01-18
EP1418174A3 (en) 2004-06-23
JP2002520410A (ja) 2002-07-09
BG110080A (bg) 2008-11-28
JP2014074047A (ja) 2014-04-24
TR200100171T2 (tr) 2001-05-21
ES2322759T3 (es) 2009-06-26
ES2214038T3 (es) 2004-09-01
BR9912010A (pt) 2001-04-10
CO5090830A1 (es) 2001-10-30
ES2372990T3 (es) 2012-01-30
SI1097148T1 (en) 2004-10-31
CY1111600T1 (el) 2015-10-07
HK1037918A1 (en) 2002-02-22
CA2510949A1 (en) 2000-01-27
PL194710B1 (pl) 2007-06-29
IL187181A0 (en) 2008-02-09
SI1418174T1 (sl) 2009-08-31
CN102153524A (zh) 2011-08-17
EP2017269B1 (en) 2011-11-23
DK2017269T3 (da) 2012-03-05
BG66140B1 (bg) 2011-07-29
PL348033A1 (en) 2002-05-06
PT2017269E (pt) 2011-12-20
PT1418174E (pt) 2009-06-08
ATE425974T1 (de) 2009-04-15
CA2337846A1 (en) 2000-01-27
PT1097148E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
AR044029A2 (es) Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
DE60230327D1 (de) Polymorphe von clopidogrel-hydrogensulfat
BG106786A (en) Process for the preparation of amorphous atorvastatin
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
FI109023B (fi) Menetelmä puhtaan sitalopraamin valmistamiseksi
ECSP093680A (es) Proceso para derivados del acido fenilacetico
YU94103A (sh) Novi derivati sulfonske kiseline
UY27410A1 (es) Formas novedosas crudas cristalinas
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
MX9306666A (es) Nuevas azetidinonas substituidas como agentes antiinflamatorios y antidegenerativos.
EE200000479A (et) Simvastatiini ja selle derivaatide saamise protsess
ES2192334T3 (es) Procedimiento mejorado para preparar un agente antiparasitario.
ES2127875T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas con amino, procedimiento para su preparacion y su utilizacion como productos farmaceuticos.
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
AR033677A1 (es) Proceso para preparar 4,6-dimetoxi-2-(metilsulfonil)-1,3-pirimidina y uso de este compuesto como intermediario en la preparación de 7-[ (4,6-dimetoxi-pirimidin-2-il)tio ]-3-metilftalida
EA200000172A2 (ru) Способ получения стимуляторов секреции гормонов роста
PE20000356A1 (es) FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL
EA200201236A1 (ru) Новый полиморф v торасемида
DK1091001T3 (da) Fremgangsmåde til rensning af S-adenosyl-L-methionin og til fremstilling af farmaceutiske acceptable salte deraf
YU70502A (sh) Amorfna modifikacija torasemida
CO4970800A1 (es) Forma termodinamicamente estable del acido (r)-3(((4-fluoro- fenil) sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazo-9-pro- panoico (ramatroban)
NO20032469D0 (no) Krystallisasjonsprosess for fremstilling av sterk konsentrert hydrogenperoksid
UY26250A1 (es) Sulfonamidas sustituidas con naftilo
AU2002368494A1 (en) A process for the preparation of cefpodoxime proxetil
PT1226135E (pt) Procedimento para a preparacao de um derivado do tiofeno

Legal Events

Date Code Title Description
FC Refusal